Biocon Biologics is betting big that it can be a top US biosimilars company.
With its $3 billion acquisition of Viatris’ biosimilar portfolio last November now fully integrated, Biocon is readying a more concerted commercial push.
It’s up against some 800-pound gorillas — the established and marketing-savvy Big Pharma biosimilar…
Click here to view original post
